GIBSON DUNN

Gibson Dunn Advises XOMA Royalty Corporation on Acquisition of HilleVax, Inc.

Firm News | August 13, 2025

Gibson Dunn is representing XOMA Royalty Corporation, a publicly traded biotech royalty aggregator, on its acquisition of HilleVax, Inc. (Nasdaq: HLVX), a biopharmaceutical company that was focused on developing and commercializing novel vaccines.

Gibson Dunn regularly advises life sciences companies and investors on complex mergers and acquisitions in the biotechnology sector.

The Gibson Dunn corporate team includes Ryan Murr, Branden Berns, and Chad Kang. Team members advising on additional aspects of the transaction include Pamela Lawrence Endreny (tax), Sean Feller and Spencer Bankhead (employee benefits), Jessica Valenzuela, Hazel Granada, and Minae Seog (litigation).

Related People

Ryan A. Murr

Branden C. Berns

Chad Kang

Pamela Lawrence Endreny

Sean C. Feller

Jessica Valenzuela

Hazel Granada

Minae Seog

Related Capabilities

Mergers and Acquisitions

Life Sciences

Tax

Executive Compensation and Employee Benefits

Litigation

Technology Transactions

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**